1. Home
  2. RVPH vs ICCM Comparison

RVPH vs ICCM Comparison

Compare RVPH & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • ICCM
  • Stock Information
  • Founded
  • RVPH 2006
  • ICCM 2006
  • Country
  • RVPH United States
  • ICCM Israel
  • Employees
  • RVPH N/A
  • ICCM N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • ICCM
  • Sector
  • RVPH Health Care
  • ICCM
  • Exchange
  • RVPH Nasdaq
  • ICCM Nasdaq
  • Market Cap
  • RVPH 36.4M
  • ICCM 36.0M
  • IPO Year
  • RVPH N/A
  • ICCM N/A
  • Fundamental
  • Price
  • RVPH $1.18
  • ICCM $0.82
  • Analyst Decision
  • RVPH Strong Buy
  • ICCM Strong Buy
  • Analyst Count
  • RVPH 3
  • ICCM 2
  • Target Price
  • RVPH $14.33
  • ICCM $2.95
  • AVG Volume (30 Days)
  • RVPH 283.9K
  • ICCM 349.1K
  • Earning Date
  • RVPH 08-12-2024
  • ICCM 08-12-2024
  • Dividend Yield
  • RVPH N/A
  • ICCM N/A
  • EPS Growth
  • RVPH N/A
  • ICCM N/A
  • EPS
  • RVPH N/A
  • ICCM N/A
  • Revenue
  • RVPH N/A
  • ICCM $3,262,000.00
  • Revenue This Year
  • RVPH N/A
  • ICCM $16.85
  • Revenue Next Year
  • RVPH N/A
  • ICCM $57.25
  • P/E Ratio
  • RVPH N/A
  • ICCM N/A
  • Revenue Growth
  • RVPH N/A
  • ICCM 7.02
  • 52 Week Low
  • RVPH $0.95
  • ICCM $0.52
  • 52 Week High
  • RVPH $6.80
  • ICCM $1.57
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 45.21
  • ICCM 55.57
  • Support Level
  • RVPH $0.95
  • ICCM $0.62
  • Resistance Level
  • RVPH $1.30
  • ICCM $0.78
  • Average True Range (ATR)
  • RVPH 0.14
  • ICCM 0.05
  • MACD
  • RVPH 0.01
  • ICCM 0.02
  • Stochastic Oscillator
  • RVPH 56.25
  • ICCM 90.91

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

Share on Social Networks: